drugset / Trial / NCT03989414
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
Timeline
- Start
- 2019-09-30
- Primary completion
- 2026-11-30
- Completion
- 2026-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mezigdomide | Small molecule | — | — |
| Background | Bortezomib | Small molecule | — | — |
| Background | Carfilzomib | Other / unclassified | — | — |
| Background | Daratumumab | Monoclonal antibody | — | — |
| Background | Dexamethasone | Small molecule | — | — |
| Background | Elotuzumab | Monoclonal antibody | — | — |
| Background | Isatuximab | Monoclonal antibody | — | — |